The DOI matches its Crossref record.
The Course of Seizure Disorders in Patients With Malignant Gliomas
Abstract
OBJECTIVE: To describe the morbidity associated with seizures and the efficacy of anticonvulsant therapy in adult patients with malignant gliomas (MGs). STUDY DESIGN: A retrospective review of charts was performed to determine the occurrence of seizures at diagnosis, the frequency and character of subsequent seizures, and the use and toxic side effects of anticonvulsants. PATIENTS: Sixty-five consecutive adult patients with supratentorial MGs who were examined in the neurooncology clinic at a university medical center were studied. The diagnosis was glioblastoma in 47 of the patients, and it was anaplastic astrocytoma in 18 patients. The mean age of the patients was 49.5 years. The median Karnofsky status score was 80. The median survival was 18 months. RESULTS: Twenty-nine patients presented with seizures, and 21 of these had subsequent (eg, "recurrent") seizures while they were receiving anticonvulsant therapy. Ten of 36 patients who were free of seizures at diagnosis experienced seizures after diagnosis (eg, "late onset") while they were being treated with anticonvulsants, including five patients who had single seizures. Long-term seizure frequency in excess of one per month was observed in 13 patients. Ten patients had episodes of partial motor status epilepticus. Most recurrent and late-onset seizures occurred despite therapeutic anticonvulsant levels, and without evidence of tumor progression. Rash associated with anticonvulsants was observed in 26% of the patients. Other clinically important toxic side effects were observed in 14% of the patients who were receiving long-term anticonvulsant therapy. CONCLUSIONS: Seizures contributed substantially to the neurologic morbidity of MGs in at least 25% of these patients. The occurrence of seizures at diagnosis was a strong predictor of subsequent seizures, and in many patients, seizures proved to be refractory to standard anticonvulsant therapy. Long-term anticonvulsant toxic side effects are relatively common in patients with MGs. The use of long-term seizure prophylaxis for patients with MGs who are free of seizures at presentation is not clearly beneficial and should be studied in a prospective trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management
van Breemen, M. S., Wilms, E. B., & Vecht, C. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70103-5 · Cited by 913
Glantz, M. J., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., Grossman, S. A., & Cairncross, J. G. (2000) · Neurology · doi:10.1212/wnl.54.10.1886 · Cited by 858
Glutamate release promotes growth of malignant gliomas
Takano, T., Lin, J. H.-C., Arcuino, G., Gao, Q., Yang, J., & Nedergaard, M. (2001) · Nature Medicine · doi:10.1038/nm0901-1010 · Cited by 601
Glutamate release by primary brain tumors induces epileptic activity
Buckingham, S. C., Campbell, S. L., Haas, B. R., Montana, V., Robel, S., Ogunrinu, T., & Sontheimer, H. (2011) · Nature Medicine · doi:10.1038/nm.2453 · Cited by 578
Glutamate and the biology of gliomas
de Groot, J., & Sontheimer, H. (2011) · Glia · doi:10.1002/glia.21113 · Cited by 293
Metadata
- Authors
- Moots, P. L., Maciunas, R. J., Eisert, D. R., Parker, R. A., Laporte, K., & Abou-Khalil, B.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 1995-07-01
- Volume
- 52
- Issue
- 7
- Pages
- 717-724
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2037433948
- Cited by
- 226
- References
- 0
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Course of Seizure Disorders in Patients With Malignant Gliomas. https://app.cochat.ai/papers/10.1001/archneur.1995.00540310091021
- The paper
- Moots, P. L., Maciunas, R. J., Eisert, D. R., Parker, R. A., Laporte, K., & Abou-Khalil, B. (1995). The Course of Seizure Disorders in Patients With Malignant Gliomas. Archives of Neurology. https://doi.org/10.1001/archneur.1995.00540310091021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.